E-viri
Recenzirano
-
Morris, Michael J; Heller, Glenn; Hillman, David W; Bobek, Olivia; Ryan, Charles; Antonarakis, Emmanuel S; Bryce, Alan H; Hahn, Olwen; Beltran, Himisha; Armstrong, Andrew J; Schwartz, Lawrence; Lewis, Lionel D; Beumer, Jan H; Langevin, Brooke; McGary, Eric C; Mehan, Paul T; Goldkorn, Amir; Roth, Bruce J; Xiao, Han; Watt, Colleen; Taplin, Mary-Ellen; Halabi, Susan; Small, Eric J
Journal of clinical oncology, 06/2023, Letnik: 41, Številka: 18Journal Article
Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. Men with untreated mCRPC were randomly assigned (1:1) to receive first-line enzalutamide with or without AAP. The primary end point was OS. Toxicity, prostate-specific antigen declines, pharmacokinetics, and radiographic progression-free survival (rPFS) were also examined. Data were analyzed using an intent-to-treat approach. The Kaplan-Meier estimate and the stratified log-rank statistic were used to compare OS between treatments. In total, 1,311 patients were randomly assigned: 657 to enzalutamide and 654 to enzalutamide plus AAP. OS was not statistically different between the two arms (median, 32.7 95% CI, 30.5 to 35.4 months for enzalutamide 34.2 95% CI, 31.4 to 37.3 months for enzalutamide and AAP; hazard ratio HR, 0.89; one-sided = .03; boundary nominal significance level = .02). rPFS was longer in the combination arm (median rPFS, 21.3 95% CI, 19.4 to 22.9 months for enzalutamide 24.3 95% CI, 22.3 to 26.7 months for enzalutamide and AAP; HR, 0.86; two-sided = .02). However, pharmacokinetic clearance of abiraterone was 2.2- to 2.9-fold higher when administered with enzalutamide, compared with clearance values for abiraterone alone. The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.